Breast Cancer Early Detection Test
Breast Cancer Detection
Pre-clinical/Clinical Trial PreparationActive
Key Facts
Indication
Breast Cancer Detection
Phase
Pre-clinical/Clinical Trial Preparation
Status
Active
Company
About Mammogen
Mammogen is a private, pre-revenue diagnostics company founded in 2019 with the ambitious goal of transforming breast cancer care through early detection. Its core technology platform centers on analyzing circulating messenger RNA (mRNA) biomarkers from biofluids like blood and saliva to identify disease signatures much earlier than current methods allow. The company is preparing for an upcoming clinical trial and positions itself not just as a biotech firm but as a movement aiming to address the full spectrum of patient experience, from scientific innovation to emotional and social support. Mammogen operates as part of the IVBH corporate studio.
View full company profileTherapeutic Areas
Other Breast Cancer Detection Drugs
| Drug | Company | Phase |
|---|---|---|
| MammoScreen | Therapixel | Approved |
| MVT-501 | Microvascular Therapeutics | Pre-clinical |
| Transpara Algorithm Enhancement | ScreenPoint Medical | Ongoing Development |
| AI-Powered Breast Imaging Algorithms | Hologic | Commercial Roll-out |